Pegloticase therapy improves physical function and health-related quality of life in patients with refractory chronic gout, according to this analysis of patient-reported-outcome data. At week 25, patients who received 8 mg pegloticase biweekly (n = 85) showed significant, clinically meaningful improvements in patient global assessment of disease activity, pain, Health Assessment Questionnaire Disability Index and physical component summary scores, whereas patients who received placebo did not (n = 43).